News
NHS accelerator programme launches call for applications
Successful applicants to the NIA will benefit from three years of support and expert mentoring
The NHS accelerator programme has launched a call for applications to the 2024 intake in a bid to “transform” healthcare delivery.
The NHS Innovation Accelerator (NIA) aims to support entrepreneurs in scaling and adopting mature innovations across NHS England.
Working with NICE, NHS England, the Academic Health Science Network (AHSN), the MHRA and industry organisations, the initiative offers a programme of support to help individuals develop a partnership-led “roadmap” to scaling across the health and social care ecosystem.
The programme provides mentoring from industry experts and a pipeline to provide health tech products to the NHS.
“At the NIA, our core belief is that no one can solve health and social care’s biggest challenges alone,” said Konrad Dobschuetz, NHS Innovation Accelerator national director.
“That’s why we champion a collaborative and mutually supportive approach to innovation that makes an impact.
“We’re looking forward to receiving another strong set of applications this year, and to meeting our new cohort of innovators who are committed to creating an NHS that is fit for the future.”
The recruitment call is focused on innovations that can address health inequalities and is open to start-ups with solutions in the field of maternity, mental health, cancer, respiratory disease, hypertension/ cardiovascular disease, diabetes, epilepsy, oral health and carbon reduction in healthcare.
Successful applicants to the NIA will benefit from three years of support, followed by access to the alumni network and peer community.
Professor Bola Owolabi, director, healthcare inequalities at NHS England, said: “The NIA is a world-leading programme that I would strongly encourage innovators to apply to.
“Its offering is uniquely positioned in several important ways and on account of the expertise in the team and amongst the mentors, the reach it has into and across the NHS, and the access it has to the health and healthtech industry.”
NIA alumni include the founder of healthcare staffing solution Locum’s Nest, the creator of skin cancer melanoma tracking app SkinVision, the founder and CEO of patient-controlled records system Patients Know Best, and the chief executive of The Organisation for the Review of Care and Health Apps (ORCHA).
According to NHS England, the NIA programme has already supported the creation of 1,244 jobs and generated revenue of more than £18m through solutions deployed across more than 3,000 NHS sites.
Applications for the 2024 edition of the accelerator close on October 22.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






